Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT04207086
Title A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma (Neo PeLe)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Melanoma Institute Australia
Age Groups: senior | adult
Covered Countries AUS

No variant requirements are available.